
According to Benzinga Pro data, during Q1, MaxCyte (NASDAQ:MXCT) posted sales of $11.59 million. Earnings were up 16.56%, but MaxCyte still reported an overall loss of $4.07 million. In Q4, MaxCyte brought in $10.15 million in sales but lost $4.87 million in earnings.